Market Overview

What's Next For Regeneron After A Therapy Trial Failure?

Share:
What's Next For Regeneron After A Therapy Trial Failure?
Related REGN
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
FDA OKs Regeneron and Sanofi's Dupixent for asthma (Seeking Alpha)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced results Monday from two mid-stage studies for diabetic macular edema and age-related macular degeneration therapies.

The combo did not provide sufficient differentiation to warrant a Phase 3 development,Regeneron said.

The Analyst

Canaccord Genuity analyst John Newman maintained a Buy rating on the shares of Regeneron and a P/E-derived price target of $522.

The Thesis

The outcome of the two studies — RUBY and ONYX — that evaluated the combo was in line with the firm's expectations, given the high bar of success posed by EYLEA control, Newman said. (See Newman's track record here.) 

Regeneron is now likely to focus on additional indications for Dupixent, including adult/adolescent uncontrolled asthma, Newman said. U.S. approval is likely in 2018, the analyst said.

Given that Amgen, Inc. (NASDAQ: AMGN)'s tezepelumab is still in Phase 2 trials as opposed to Dupixent being tested in Phase 3 trials, Newman expects the latter to enter the market earlier, lending upside to the stock price.

Dupixent showed efficacy similar to tezepelumab in patients with severe asthma and those with high eosinophil counts, although Amgen's scored over in terms of efficacy in the overall population.

The Price Action

Regeneron shares are in the red year-to-date, having dropped roughly 1 percent.

At the time of writing, the shares of the company were down 3.48 percent at $361.48.

Related Links:

Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside

Latest Ratings for REGN

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018Canaccord GenuityMaintainsHoldHold
Oct 2018Cantor FitzgeraldInitiates Coverage OnNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity John NewmanAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (AMGN + REGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ETTXWedbushInitiates Coverage On19.0
WINGWedbushDowngrades0.0
BMYCitigroupDowngrades57.0
INTCNomuraUpgrades0.0
HRZNKeefe Bruyette & WoodsDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

What's The Difference Between Bitcoin And Bitcoin Cash? Which Is The Better Investment?

While Big Banks Fight Regulations, Fintech Conquers Them